168 related articles for article (PubMed ID: 31281023)
1. Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase.
Sasaki T; Gannam ZTK; Kudalkar SN; Frey KM; Lee WG; Spasov KA; Jorgensen WL; Anderson KS
Bioorg Med Chem Lett; 2019 Aug; 29(16):2182-2188. PubMed ID: 31281023
[TBL] [Abstract][Full Text] [Related]
2. Exploring novel HIV-1 reverse transcriptase inhibitors with drug-resistant mutants: A double mutant surprise.
Hollander K; Chan AH; Frey KM; Hunker O; Ippolito JA; Spasov KA; Yeh YJ; Jorgensen WL; Ho YC; Anderson KS
Protein Sci; 2023 Dec; 32(12):e4814. PubMed ID: 37861472
[TBL] [Abstract][Full Text] [Related]
3. Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants.
Frey KM; Puleo DE; Spasov KA; Bollini M; Jorgensen WL; Anderson KS
J Med Chem; 2015 Mar; 58(6):2737-45. PubMed ID: 25700160
[TBL] [Abstract][Full Text] [Related]
4. Torsional flexibility of undecorated catechol diether compound as potent NNRTI targeting HIV-1 reverse transcriptase.
Somboon T; Saparpakorn P; Hannongbua S
J Mol Graph Model; 2019 Jan; 86():286-297. PubMed ID: 30445408
[TBL] [Abstract][Full Text] [Related]
5. Structure-based evaluation of C5 derivatives in the catechol diether series targeting HIV-1 reverse transcriptase.
Frey KM; Gray WT; Spasov KA; Bollini M; Gallardo-Macias R; Jorgensen WL; Anderson KS
Chem Biol Drug Des; 2014 May; 83(5):541-9. PubMed ID: 24289305
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel bifunctional HIV-1 reverse transcriptase inhibitors.
Lai MT; Tawa P; Auger A; Wang D; Su HP; Yan Y; Hazuda DJ; Miller MD; Asante-Appiah E; Melnyk RA
J Antimicrob Chemother; 2018 Jan; 73(1):109-117. PubMed ID: 29029095
[TBL] [Abstract][Full Text] [Related]
7. Energetics of mutation-induced changes in potency of lersivirine against HIV-1 reverse transcriptase.
Kar P; Knecht V
J Phys Chem B; 2012 Jun; 116(22):6269-78. PubMed ID: 22574920
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions.
Lai MT; Munshi V; Lu M; Feng M; Hrin-Solt R; McKenna PM; Hazuda DJ; Miller MD
Viruses; 2016 Sep; 8(10):. PubMed ID: 27669286
[TBL] [Abstract][Full Text] [Related]
9. Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.
Gao P; Song S; Frutos-Beltrán E; Li W; Sun B; Kang D; Zou J; Zhang J; Pannecouque C; De Clercq E; Menéndez-Arias L; Zhan P; Liu X
Bioorg Med Chem; 2021 Jan; 30():115927. PubMed ID: 33352387
[TBL] [Abstract][Full Text] [Related]
10. Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission.
D'Cruz OJ; Uckun FM
Curr HIV Res; 2006 Jul; 4(3):329-45. PubMed ID: 16842085
[TBL] [Abstract][Full Text] [Related]
11. Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
Chen X; Ding L; Tao Y; Pannecouque C; De Clercq E; Zhuang C; Chen FE
Eur J Med Chem; 2020 Sep; 202():112549. PubMed ID: 32712537
[TBL] [Abstract][Full Text] [Related]
12. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Balzarini J
Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
[TBL] [Abstract][Full Text] [Related]
13. Design strategies of novel NNRTIs to overcome drug resistance.
Zhan P; Liu X; Li Z; Pannecouque C; De Clercq E
Curr Med Chem; 2009; 16(29):3903-17. PubMed ID: 19747133
[TBL] [Abstract][Full Text] [Related]
14. Structural and Preclinical Studies of Computationally Designed Non-Nucleoside Reverse Transcriptase Inhibitors for Treating HIV infection.
Kudalkar SN; Beloor J; Chan AH; Lee WG; Jorgensen WL; Kumar P; Anderson KS
Mol Pharmacol; 2017 Apr; 91(4):383-391. PubMed ID: 28167742
[TBL] [Abstract][Full Text] [Related]
15. Diaryl ethers with carboxymethoxyphenacyl motif as potent HIV-1 reverse transcriptase inhibitors with improved solubility.
Frączek T; Kamiński R; Krakowiak A; Naessens E; Verhasselt B; Paneth P
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):9-16. PubMed ID: 29098886
[TBL] [Abstract][Full Text] [Related]
16. Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
Lai MT; Munshi V; Touch S; Tynebor RM; Tucker TJ; McKenna PM; Williams TM; DiStefano DJ; Hazuda DJ; Miller MD
Antimicrob Agents Chemother; 2009 Jun; 53(6):2424-31. PubMed ID: 19289522
[TBL] [Abstract][Full Text] [Related]
17. Structure-Based Optimization of 2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Exploiting the Tolerant Regions of the Non-Nucleoside Reverse Transcriptase Inhibitors' Binding Pocket.
Zhao F; Zhang H; Xie M; Meng B; Liu N; Dun C; Qin Y; Gao S; De Clercq E; Pannecouque C; Tang YJ; Zhan P; Liu X; Kang D
J Med Chem; 2023 Feb; 66(3):2102-2115. PubMed ID: 36700940
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
Meng Q; Chen X; Kang D; Huang B; Li W; Zhan P; Daelemans D; De Clercq E; Pannecouque C; Liu X
Eur J Med Chem; 2016 Jun; 115():53-62. PubMed ID: 26994843
[TBL] [Abstract][Full Text] [Related]
19. Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant.
Ragno R; Mai A; Sbardella G; Artico M; Massa S; Musiu C; Mura M; Marturana F; Cadeddu A; La Colla P
J Med Chem; 2004 Feb; 47(4):928-34. PubMed ID: 14761194
[TBL] [Abstract][Full Text] [Related]
20. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
Tabassum T; Azeem SM; Muwonge AN; Frey KM
Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
